Successful treatment of late, recurrent wilms tumor with high-dose chemotherapy and autologous stem cell rescue in third complete response.

Abstract

SUMMARY:

Wilms tumor relapses are infrequent, occurring in approximately 15% of favorable histology patients. Very few cases of late recurrent relapse exist in the literature. Long-term survival after autologous stem cell rescue ranges from 40% to 73%, but there are very few reports of patients transplanted in their third complete response. We report a late recurrent relapse of Wilms tumor successfully treated with high-dose chemotherapy and autologous stem cell rescue in his third complete response who remains disease free 15 months posttransplant.

• Authors: Evangeline Brown, Andre Hebra, Joseph Jenrette, Michelle Hudspeth
• Journal: Journal of pediatric hematology/oncology (J Pediatr Hematol Oncol) Vol. 32 Issue 6 Pg. e241-3 (Aug 2010) ISSN: 1536-3678 [Electronic] United States
• PMID: 20628317 (Publication Type: Case Reports, Journal Article)

Chemical References

• Etoposide
• Carboplatin
• Melphalan

Topics

• Adolescent
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Carboplatin (administration & dosage)
• Child, Preschool
• Combined Modality Therapy
• Etoposide (administration & dosage)
• Hematopoietic Stem Cell Transplantation
• Humans
• Kidney Neoplasms (therapy)
• Male
• Melphalan (administration & dosage)
• Neoplasm Recurrence, Local (therapy)
• Salvage Therapy (methods)
• Wilms Tumor (therapy)